Trial to Evaluate L9LS in Healthy Adults

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-13

Study Completion Date

2022-09-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

Malaria is a parasitic disease carried by mosquitoes in tropical areas. There is no vaccine to prevent malaria infection. If not treated right away, it can become serious or deadly. Researchers want to test a drug to prevent malaria.

Objective:

To test if the drug L9LS is safe and if it prevents malaria infection in people.

Eligibility:

Healthy adults ages 18-50 who have never had malaria.

Design:

Participants were screened with a medical history, physical exam, and blood tests.

Participants were divided into 6 groups:

* Three groups received L9LS by infusion into a vein, and gave blood samples before and after infusion.
* One group received L9LS injected into the fat under the skin.
* One group did not get L9LS.
* One group received L9LS injected into the muscle.

All participants who received L9LS were monitored for side effects. They had 2-3 follow-up visits during the week after the drug was given, and gave blood samples. They received a thermometer to check their temperature daily for 7 days. They received a tool to measure any redness, swelling, or bruising at the injection site.

Most participants took part in the controlled human malaria infection (CHMI) or malaria challenge to find out if L9LS prevents malaria after being bitten by infected mosquitos. Participants in the group who received L9LS injected in the muscle were enrolled after CHMI and did not take part in the CHMI. Participants who received CHMI were bitten by mosquitoes carrying the malaria parasites. A cup containing mosquitoes was placed on their arm for 5 minutes. On days 7-17 after exposure, they received daily study visits to give blood samples. Those who got malaria were treated immediately. On day 21, all CHMI participants received treatment for malaria.

Participation lasted 2-6 months, depending on study group.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

L9LS MAb in Malian Adults

NCT05816330

Plasmodium Falciparum Infection Malaria

COMPLETED PHASE2

Trial to Evaluate CIS43LS in Healthy Adults

NCT04206332

Malaria

COMPLETED PHASE1

Anti-malaria MAb in Malian Children

NCT05304611

Plasmodium Falciparum Infection Malaria

COMPLETED PHASE2

L9LS in Women of Childbearing Potential in Mali

NCT07060508

Malaria

RECRUITING PHASE2

L9LS-R21 Interaction

NCT07208760

Malaria

NOT_YET_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This was a Phase 1, open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and protective efficacy of an anti-malaria human monoclonal antibody, VRC-MALMAB0114-00-AB (L9LS). The primary hypothesis was that L9LS will be safe and well tolerated when administered by either intravenous (IV),subcutaneous (SC) or intramuscular (IM) routes. The secondary objectives were that L9LS will be detectable in human sera with a definable half-life and confer protection following a controlled human malaria infection (CHMI).

The study started with enrollment into Group 1. Interim safety evaluations occurred and supported continued evaluation of L9LS prior to enrolling participants into additional dose groups. All L9LS recipients in Groups 1-4 were invited to participate in the CHMI. Group 5 participants did not receive L9LS, in order to serve as the control group for the CHMI. After CHMI, all CHMI participants were evaluated for malaria parasitemia. Participants who developed blood stage infection were treated as soon as identified per protocol criteria. Participants in Group 6 received L9LS but did not take part in the CHMI.

Study follow-up continued through 24 weeks post product administration or 8 weeks post- CHMI, whichever was the most stringent.

Study Groups:

Group 1: 5 participants - 1mg/kg IV + CHMI

Group 2: 4 participants - 5 mg/kg IV + CHMI (1 participant declined to participate in the CHMI)

Group 3: 5 participants - 5 mg/ kg SC + CHMI

Group 4: 4 participants - 20 mg/kg IV + CHMI

Group 5: 9 participants - CHMI Controls (No L9LS given; 3 back up participants were not needed so were terminated early and did not participate in the CHMI)

Group 6: 5 participants - 5 mg/kg IM

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malaria

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1: L9LS (1 mg/kg IV)

L9LS (1 mg/kg) administered by intravenous (IV) infusion (Day 0)

Group Type EXPERIMENTAL

VRC-MALMAB0114-00-AB

Intervention Type DRUG

VRC-MALMAB0114-00-AB (L9LS) is a monoclonal antibody that binds an epitope of the Plasmodium falciparum circumsporozoite protein.

Plasmodium falciparum (P. falciparum) sporozoite challenge

Intervention Type OTHER

Participants were exposed to bites on the forearm from mosquitoes infected with Plasmodium falciparum

Group 2: L9LS (5 mg/kg IV)

L9LS (5 mg/kg) administered by IV infusion (Day 0)

Group Type EXPERIMENTAL

VRC-MALMAB0114-00-AB

Intervention Type DRUG

VRC-MALMAB0114-00-AB (L9LS) is a monoclonal antibody that binds an epitope of the Plasmodium falciparum circumsporozoite protein.

Plasmodium falciparum (P. falciparum) sporozoite challenge

Intervention Type OTHER

Participants were exposed to bites on the forearm from mosquitoes infected with Plasmodium falciparum

Group 3: L9LS (5 mg/kg SC)

L9LS (5 mg/kg) administered by subcutaneous (SC) injection (Day 0)

Group Type EXPERIMENTAL

VRC-MALMAB0114-00-AB

Intervention Type DRUG

VRC-MALMAB0114-00-AB (L9LS) is a monoclonal antibody that binds an epitope of the Plasmodium falciparum circumsporozoite protein.

Plasmodium falciparum (P. falciparum) sporozoite challenge

Intervention Type OTHER

Participants were exposed to bites on the forearm from mosquitoes infected with Plasmodium falciparum

Group 4: L9LS (20 mg/kg IV)

L9LS (20 mg/kg) administered by IV infusion (Day 0)

Group Type EXPERIMENTAL

VRC-MALMAB0114-00-AB

Intervention Type DRUG

VRC-MALMAB0114-00-AB (L9LS) is a monoclonal antibody that binds an epitope of the Plasmodium falciparum circumsporozoite protein.

Plasmodium falciparum (P. falciparum) sporozoite challenge

Intervention Type OTHER

Participants were exposed to bites on the forearm from mosquitoes infected with Plasmodium falciparum

Group 5: CHMI Controls

Control participants who did not receive L9LS and were enrolled to complete the controlled human malaria infection (CHMI)

Group Type OTHER

Plasmodium falciparum (P. falciparum) sporozoite challenge

Intervention Type OTHER

Participants were exposed to bites on the forearm from mosquitoes infected with Plasmodium falciparum

Group 6: L9LS (5 mg/kg IM)

L9LS (5 mg/kg) administered by intramuscular (IM) injection (Day 0)

Group Type EXPERIMENTAL

VRC-MALMAB0114-00-AB

Intervention Type DRUG

VRC-MALMAB0114-00-AB (L9LS) is a monoclonal antibody that binds an epitope of the Plasmodium falciparum circumsporozoite protein.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VRC-MALMAB0114-00-AB

VRC-MALMAB0114-00-AB (L9LS) is a monoclonal antibody that binds an epitope of the Plasmodium falciparum circumsporozoite protein.

Intervention Type DRUG

Plasmodium falciparum (P. falciparum) sporozoite challenge

Participants were exposed to bites on the forearm from mosquitoes infected with Plasmodium falciparum

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

L9LS

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

A volunteer must have met all of the following criteria to be included:

1. Able and willing to complete the informed consent process
2. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process
3. Available for clinical follow-up through the last study visit
4. 18 to 50 years of age
5. In good general health without clinically significant medical history
6. Physical examination without clinically significant findings within the 56 days prior to enrollment
7. Weight \<= 115 kg (except Group 5)
8. Adequate venous access if assigned to an IV group or adequate subcutaneous tissue if assigned to an SC group
9. Willing to have blood samples collected, stored indefinitely, and used for research purposes
10. Agrees to participate in a controlled human malaria infection (CHMI) and to comply with post-CHMI follow-up requirements (except Group 6)
11. Agrees to refrain from blood donation to blood banks for 3 years following participation in CHMI (except Group 6)
12. Agrees not to travel to a malaria endemic region during the entire course of study participation (except Group 6)

Laboratory Criteria within 56 days prior to enrollment:
13. White Blood Cell (WBC) 2,500-12,000/mm\^3
14. WBC differential either within institutional normal range or accompanied by the Principal Investigator (PI) or designee approval
15. Platelets = 125,000-500,000/mm\^3
16. Hemoglobin within institutional normal range or accompanied by the PI or designee approval
17. Creatinine \<= 1.1 x upper limit of normal (ULN)
18. Alanine aminotransferase (ALT) \<=1.25 x ULN
19. Negative for HIV infection by an FDA approved method of detection

Laboratory Criteria documented any time during screening, prior to enrollment:
20. Negative polymerase chain reaction (PCR) for malaria (except Group 6)
21. Negative sickle cell screening test (except Group 6)
22. Electrocardiogram (ECG) without clinically significant abnormalities (examples may include: pathologic Q waves, significant ST-T wave changes, left ventricular hypertrophy, any non-sinus rhythm excluding isolated premature atrial contractions, right or left bundle branch block, advanced A-V heart block). ECG abnormalities determined by a cardiologist to be clinically insignificant as related to study participation do not preclude study enrollment (except Group 6)
23. No evidence of increased cardiovascular disease risk; defined as \>10% five-year risk by the non-laboratory method (except Group 6)

Criteria Specific to Women:
24. Postmenopausal for at least 1 year, post-hysterectomy or bilateral oophorectomy, or if of childbearing potential:

1. Negative beta-human chorionic gonadotropin (beta-HCG) pregnancy test (urine or serum) on day of enrollment, and prior to product administration and CHMI, and
2. Agrees to use an effective means of birth control through the duration of study participation

Exclusion Criteria

A volunteer would have been excluded if one or more of the following conditions applied:

1. Woman who is breast-feeding or planning to become pregnant during study participation
2. Previous receipt of a malaria vaccine or anti-malaria monoclonal antibody
3. History of malaria infection
4. Any history of a severe allergic reaction with generalized urticaria, angioedema or anaphylaxis prior to enrollment that has a reasonable risk of recurrence during the study
5. Hypertension that is not well controlled
6. Receipt of any investigational study product within 28 days prior to enrollment/product administration (Note: SARS-CoV-2 vaccines approved by emergency use authorization are not exclusionary)
7. Receipt of any live attenuated vaccines within 28 days prior to enrollment/product administration
8. Receipt of any vaccine within 2 weeks prior to enrollment/product administration
9. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with intramuscular injections or blood draws
10. History of a splenectomy, sickle cell disease or sickle cell trait
11. History of skeeter syndrome or anaphylactic response to mosquito-bites (except Group 6)
12. Known intolerance to chloroquine phosphate, atovaquone or proguanil (except Group 6)
13. Use or planned use of any drug with antimalarial activity that would coincide with study product or CHMI (except Group 6)
14. History of psoriasis or porphyria, which may be exacerbated after treatment with chloroquine (except Group 6)
15. Anticipated use of medications known to cause drug reactions with chloroquine or atovaquone-proguanil (Malarone) such as cimetidine, metoclopramide, antacids, and kaolin
16. History of Sjogren's Syndrome
17. History of chronic or recurrent salivary gland disorder diagnosed by a clinician (note: an isolated occurrence of parotitis, sialadenitis, sialolithiasis, or of a salivary gland tumor is not exclusionary)
18. History of therapeutic head or neck radiation
19. Any other chronic or clinically significant medical condition that in the opinion of the investigator would jeopardize the safety or rights of the volunteer, including but not limited to: diabetes mellitus type I, chronic hepatitis; OR clinically significant forms of: drug or alcohol abuse, asthma, autoimmune disease, infectious diseases, psychiatric disorders, heart disease, or cancer

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes